Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24
Smolen J, Behrens F, Liu-Leage S, Sapin C, De La Torre I, Meszaros G, Schett G, Gossec L, Ostor A, Combe B, Van Den Bosch F (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: WILEY
City/Town: HOBOKEN
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Authors with CRIS profile
Involved external institutions
Eli Lilly and Company
United States (USA) (US)
University Hospital Ghent
Belgium (BE)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Monash University
Australia (AU)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Medizinische Universität Wien
Austria (AT)
University of Montpellier / Université Montpellier
France (FR)
United States (USA) (US)
University Hospital Ghent
Belgium (BE)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Monash University
Australia (AU)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Medizinische Universität Wien
Austria (AT)
University of Montpellier / Université Montpellier
France (FR)
How to cite
APA:
Smolen, J., Behrens, F., Liu-Leage, S., Sapin, C., De La Torre, I., Meszaros, G.,... Van Den Bosch, F. (2020). Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.
MLA:
Smolen, Josef, et al. "Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2020.
BibTeX: Download